Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Franklin Resources Inc.

Franklin Resources Inc. raised its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 19.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 188,141 shares of the company's stock after buying an additional 30,530 shares during the quarter. Franklin Resources Inc. owned about 0.61% of Medpace worth $66,508,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. State Street Corp grew its position in Medpace by 7.2% during the 3rd quarter. State Street Corp now owns 752,957 shares of the company's stock worth $251,337,000 after purchasing an additional 50,312 shares during the last quarter. Geode Capital Management LLC lifted its position in Medpace by 7.6% during the 3rd quarter. Geode Capital Management LLC now owns 628,054 shares of the company's stock worth $209,885,000 after acquiring an additional 44,371 shares during the period. Renaissance Technologies LLC grew its stake in Medpace by 38.3% during the 2nd quarter. Renaissance Technologies LLC now owns 443,588 shares of the company's stock valued at $182,692,000 after purchasing an additional 122,800 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Medpace by 36.0% in the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company's stock worth $138,612,000 after purchasing an additional 109,886 shares during the last quarter. Finally, Clearbridge Investments LLC lifted its holdings in shares of Medpace by 55.1% during the second quarter. Clearbridge Investments LLC now owns 403,892 shares of the company's stock worth $166,343,000 after purchasing an additional 143,481 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Trading Down 0.4 %

MEDP stock traded down $1.26 during mid-day trading on Tuesday, reaching $348.48. The company's stock had a trading volume of 352,526 shares, compared to its average volume of 282,347. Medpace Holdings, Inc. has a fifty-two week low of $277.72 and a fifty-two week high of $459.77. The stock has a market cap of $10.83 billion, a PE ratio of 30.63, a P/E/G ratio of 1.89 and a beta of 1.37. The company's 50 day moving average is $339.54 and its two-hundred day moving average is $367.41.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.77 by $0.24. The firm had revenue of $533.32 million during the quarter, compared to the consensus estimate of $540.99 million. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The company's quarterly revenue was up 8.3% on a year-over-year basis. During the same period last year, the company earned $2.22 EPS. On average, analysts forecast that Medpace Holdings, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MEDP has been the topic of several recent research reports. Robert W. Baird upped their price objective on shares of Medpace from $349.00 to $354.00 and gave the company a "neutral" rating in a report on Monday, November 25th. Baird R W lowered shares of Medpace from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 23rd. Redburn Atlantic assumed coverage on shares of Medpace in a research note on Monday, October 14th. They set a "buy" rating and a $404.00 target price on the stock. TD Cowen lowered their price target on Medpace from $413.00 to $372.00 and set a "buy" rating on the stock in a research report on Wednesday, October 23rd. Finally, UBS Group cut Medpace from a "buy" rating to a "neutral" rating and cut their price objective for the company from $420.00 to $350.00 in a research report on Friday, September 27th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $380.56.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.